Keybank National Association OH Lowers Stock Holdings in Baxter International Inc (NYSE:BAX)

Keybank National Association OH trimmed its position in Baxter International Inc (NYSE:BAX) by 3.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 61,470 shares of the medical instruments supplier’s stock after selling 2,202 shares during the quarter. Keybank National Association OH’s holdings in Baxter International were worth $5,377,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in BAX. Kornitzer Capital Management Inc. KS raised its stake in Baxter International by 82.8% in the third quarter. Kornitzer Capital Management Inc. KS now owns 582,203 shares of the medical instruments supplier’s stock valued at $50,925,000 after purchasing an additional 263,756 shares in the last quarter. Bartlett & Co. LLC raised its stake in Baxter International by 2.4% in the third quarter. Bartlett & Co. LLC now owns 561,743 shares of the medical instruments supplier’s stock valued at $49,136,000 after purchasing an additional 13,351 shares in the last quarter. Huntington National Bank raised its stake in Baxter International by 0.8% in the third quarter. Huntington National Bank now owns 497,445 shares of the medical instruments supplier’s stock valued at $43,512,000 after purchasing an additional 3,707 shares in the last quarter. Parallel Advisors LLC raised its stake in Baxter International by 2.9% in the third quarter. Parallel Advisors LLC now owns 6,994 shares of the medical instruments supplier’s stock valued at $612,000 after purchasing an additional 196 shares in the last quarter. Finally, Beese Fulmer Investment Management Inc. raised its stake in Baxter International by 0.9% in the third quarter. Beese Fulmer Investment Management Inc. now owns 67,068 shares of the medical instruments supplier’s stock valued at $5,866,000 after purchasing an additional 597 shares in the last quarter. 83.45% of the stock is currently owned by hedge funds and other institutional investors.

NYSE BAX traded up $0.51 on Friday, reaching $78.51. 3,017,392 shares of the company’s stock traded hands, compared to its average volume of 2,768,937. Baxter International Inc has a 12 month low of $61.40 and a 12 month high of $89.93. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.78 and a quick ratio of 2.10. The stock has a 50-day simple moving average of $84.08 and a 200 day simple moving average of $82.11. The stock has a market cap of $39.56 billion, a PE ratio of 25.74, a P/E/G ratio of 2.00 and a beta of 0.97.

In other news, SVP Jacqueline Kunzler sold 5,934 shares of the firm’s stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $88.12, for a total value of $522,904.08. Following the transaction, the senior vice president now owns 3,089 shares in the company, valued at $272,202.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director James R. Gavin III sold 7,950 shares of the firm’s stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $87.63, for a total transaction of $696,658.50. Following the completion of the transaction, the director now owns 40,932 shares in the company, valued at approximately $3,586,871.16. The disclosure for this sale can be found here. Insiders have sold 17,396 shares of company stock worth $1,528,575 over the last quarter. Company insiders own 0.70% of the company’s stock.

A number of equities research analysts recently weighed in on BAX shares. UBS Group lowered their target price on shares of Baxter International from $98.00 to $95.00 and set a “buy” rating on the stock in a research note on Monday, October 28th. Credit Suisse Group raised their target price on shares of Baxter International from $84.00 to $95.00 and gave the company an “outperform” rating in a research note on Friday, July 26th. Piper Jaffray Companies reaffirmed a “buy” rating on shares of Baxter International in a research note on Tuesday, September 10th. JPMorgan Chase & Co. set a $94.00 price target on shares of Baxter International and gave the company a “buy” rating in a research report on Tuesday, October 8th. Finally, BMO Capital Markets increased their price target on shares of Baxter International to $95.00 and gave the company an “outperform” rating in a research report on Friday, July 26th. Five investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $90.14.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.

Further Reading: What are the reasons investors use put options?

Institutional Ownership by Quarter for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply